Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...

After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...

After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) reports nearly US$1b in first full year Rezdiffra sales. The company launches Rezdiffra in Germany, its first market in Europe. Madrigal secures extended US ...

By reaching the brink of $1 billion in annual sales, the threshold for blockbuster drugs, Rezdiffra has given Madrigal its ...

Total Revenues: Madrigal generated fourth-quarter and full-year 2025 net revenues of $321.1 million and $958.4 million, respectively. Net revenues in the comparable prior year periods were $103.3 ...

Today, I'll provide an update on the Rezdiffra launch, where we ended our first full year on the market at nearly $1 billion in net sales and solidified Rezdiffra as the foundational therapy in MASH.

The FDA approved Rezdiffra to treat non-cirrhotic non-alcoholic steatohepatitis (NASH). Photo courtesy of U.S. Food and Drug Administration/Flickr Millions of Americans whose livers develop scar ...

Madrigal Pharmaceuticals MDGL announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) and its subsidiary, Ribocure Pharmaceuticals AB (Ribocure), covering six ...

Credit: Madrigal Pharmaceuticals. Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network. Rezdiffra should be avoided in ...